High-Tech Gründerfonds and Bayern Kapital have invested in Curefab GmbH, a start-up which is developing tools to enhance early diagnosis and prevention of stroke.
Early diagnosis in combination with appropriate therapy can reduce stroke-related risks and damage significantly. Curefab’s screening technology uses historical ultrasound data to provide information about anatomical structures and their condition over a long period of time for stroke screening programmes.
“Today’s imaging options either expose the patient to irradiation, or are complex, time consuming, and expensive. Curefab has found an elegant method which will revolutionise the diagnostic standard in this field,” says Robert Grueter, Co-Founder of Curefab.
The first prototype was developed for the German Heart Centre Munich in 2008. With support from leading medical centres such as the University Hospital Klinikum rechts der Isar in Munich, the functionality was further enhanced.
“After having proved the technical and clinical feasibility of our inventions, we were very thankful for having received the trust and financial support of our investors,” says Michael Hohenester, CEO of Curefab.
Under the leadership of High-Tech Gründerfonds and Bayern Kapital, co-investors First Value AG, Capital Rangers GmbH and optical imaging expert Framos have invested in Curefab.Curefab will now focus on optimising and expanding the clinical capabilities and application range of its product.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
